Related Experiment Video
Updated: May 1, 2026

Manufacture and Drug Delivery Applications of Silk Nanoparticles
Published on: October 8, 2016
Recent trends in drug delivery system using protein nanoparticles
S Sripriyalakshmi1, Pinkybel Jose, Aswathy Ravindran
1Center for Nanotechnology and Advanced Biomaterials (CeNTAB), School of Chemical and Biotechnology, SASTRA University, Tirumalaisamudram, Thanjavur, 613401, Tamilnadu, India.
Abstract:
Engineered nanoparticles that can facilitate drug formulation and passively target tumours have been under extensive research in recent years. These successes have driven a new wave of significant innovation in the generation of advanced particles. The fate and transport of diagnostic nanoparticles would significantly depend on nonselective drug delivery, and hence the use of high drug dosage is implemented. In this perspective, nanocarrier-based drug targeting strategies can be used which improve the selective delivery of drugs to the site of action, i.e. drug targeting. Pharmaceutical industries majorly focus on reducing the toxicity and side effects of drugs but only recently it has been realised that carrier systems themselves may pose risks to the patient. Proteins are compatible with biological systems and they are biodegradable. They offer a multitude of moieties for modifications to tailor drug binding, imaging or targeting entities. Thus, protein nanoparticles provide outstanding contributions as a carrier for drug delivery systems. This review summarises recent progress in particle-based therapeutic delivery and discusses important concepts in particle design and biological barriers for developing the next generation of particles drug delivery systems.
Related Concept Videos
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Modified-Release Drug Delivery Systems: Site-Targeted
Modified-Release Drug Delivery Systems: Overview
Drug Delivery Systems: Different Types
Oral Drug Delivery Systems: Introduction
Modified-Release Drug Delivery Systems: Rate-Programmed II

